Opens in a new tab

EOFlow v Insulet (CoA, 26 February 2026)

Date26 February 2026
CourtCoA
DivisionLuxembourg (LU)
Type of actionRequest for a discretionary review (RoP 220.3)
Case number(s)UPC_CoA_34/2026
Registry referenceUPC-COA-0000034/2026
PartiesEOFlow Co., Ltd. v. Insulet Corporation

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 26 February 2026 (UPC_CoA_34/2026), the standing judge of the Court of Appeal dismissed as inadmissible EOFlow’s request for discretionary review and its auxiliary request for leave to appeal. Both targeted the Milan Central Division’s order of 4 December 2025, which set penalty payments of EUR 150,000 for non-compliance with provisional measures (EP 4 201 327) and ordered EOFlow to pay EUR 10,000 in costs. The order confirms that review under Rule 220.3 presupposes a refusal of leave by the Court of First Instance, sought within the 15-day period.

Question

Can a party that failed to seek leave to appeal from the first instance in time obtain discretionary review or, failing that, leave to appeal from the Court of Appeal itself?

Decision

Discretionary review is available only where the first instance has refused leave. EOFlow did not request leave within 15 days, and the Court left open the position where the first instance fails to rule within that period (paragraph 16). Total v Texas Instruments is not comparable: nothing prevented EOFlow, which was represented by counsel, from seeking leave (paragraph 17). Article 73(2)(b) UPCA and Rule 220.2 leave the decision on leave to the court that issued the order. The Court of Appeal deals with leave only within an admissible discretionary review (paragraph 18). There was no need to rule on the confidentiality requests at this stage (paragraph 19).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 58 and 73(2)(b)
Rules of Procedure
Rules 220.2, 220.3, 262, 262.2, 262A and 354.4
Case law cited
Suinno v Microsoft, Court of Appeal, 9 October 2024, Total v Texas Instruments, Court of Appeal, 14 January 2025, Insulet v A. Menarini Diagnostics, Court of Appeal, 9 January 2025, EOFlow v Insulet, Court of Appeal, 4 February 2026

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CoA_34/2026 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Request for a discretionary review (RoP 220.3)
Outcome (Dhenne Avocats summary)
La demande de réexamen discrétionnaire est irrecevable faute de demande d'autorisation présentée à la première instance dans les 15 jours, et la cour d'appel ne peut accorder elle-même l'autorisation d'appel, réservée par l'article 73, paragraphe 2, sous b), de l'Accord à la juridiction qui a rendu l'ordonnance.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.